Novartis shares traded slightly lower this morning despite the company reporting a good set of third-quarter results.
The Swiss pharmaceuticals giant said it would likely not come to a decision about the future of its underperforming Alcon eyecare unit until 2019.
Novartis shares were trading around 1.3% lower this morning.
Despite reporting better-than-expected third-quarter sales and earnings, Novartis warned that sales from its Sandoz generics unit could fall slightly this year.
In common with rivals, Novartis cited pricing pressures on US generic drugs prices.